Cdki pathway inhibitors as selective inhibitors of tumor...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/4045 (2006.01) A61K 31/7088 (2006.01) A61P 35/00 (2006.01) C12Q 1/48 (2006.01)

Patent

CA 2652339

The invention provides new methods for inhibiting the CDKI pathway and specifically inhibiting tumor cell growth. The invention further provides new and specific inhibitors of tumor cell growth, as well as means for discovery of additional such inhibitors. The present inventors have surprisingly discovered that Cyclin-Dependent Kinase 3 (CDK3) is specifically required for tumor cell growth, in contrast to other members of the CDK family.

Cette invention concerne des nouvelles méthodes pour inhiber la voie des CDKI et plus spécifiquement pour inhiber la croissance des cellules tumorales. Cette invention concerne également des nouveaux inhibiteurs de la croissance des cellules tumorales spécifiques, ainsi que des moyens permettant de découvrir d'autres inhibiteurs identiques. Par rapport aux autres membres de la famille des CDK, la kinase 3 dépendante des cyclines 3 (CDK3) s'est révélée être plus particulièrement utile pour la croissance des cellules tumorales.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Cdki pathway inhibitors as selective inhibitors of tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cdki pathway inhibitors as selective inhibitors of tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cdki pathway inhibitors as selective inhibitors of tumor... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1374815

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.